Contact Information

• Office:Room 431, Researching Building 18

• Email: maofei@ecust.edu.cn

• Office Phone: +86 21 6425 2584

• Office Fax: +86 21 6425 2584

Education

• 2014.06Ph.D. Medicinal Chemistry, Sun Yat-sen University, Guangzhou, R.P. China

• 2009.06B.S. Applied Chemistry, Shenyang Pharmaceutical University, Shenyang, P. R. China

Professional Experience

• 2018-nowAssociate Professor, East China University of Science and Technology, Shanghai, P. R. China

• 2016-2018  Assistant Professor, East China University of Science and Technology, Shanghai, P. R. China

• 2014-2016  Postdoctor, East China University of Science and Technology, Shanghai, P. R. China

Research Interests

• Discovery of potential agents for the treatment of endometrial cancer

• Discovery of multi-target anti-Alzheimer’s disease candidates

• Repurposing and redevelopment of old drugs

Publication

1. Wenwen Liu^#, Huan Wang^#, Xiaokang Li^#, Yixiang Xu, Jian Zhang, Wei Wang, Qi Gong, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. Bioorg. Med. Chem. 2018, 26, 3117–3125.

2. Wei Ni^#, Huan Wang^#, Xiaokang Li^#, Xinyu Zheng^#, Manjiong Wang, Jian Zhang, Qi Gong, Dazheng Ling, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5). ACS Chem. Neurosci. 2018, 9, 1625–1636.

3. Baoli Li^#, Shuaishuai Ni^#, Fei Mao^#, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*. Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J. Med. Chem. 2018, 61, 224–250.

4. Fei Mao^#, Huan Wang^#, Wei Ni^#, Xinyu Zheng, Manjiong Wang, Keting Bao, Dazheng Ling, Xiaokang Li, Yixiang Xu, Haiyan Zhang*, Jian Li*. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 2018, 9, 328–345.

5. Hanwen Wei^#, Fei Mao^#, Shuaishuai Ni^#, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections. Eur. J. Med. Chem. 2018, 145, 235–251.

6. Yi-xiang Xu^#, Huan Wang^#, Xiao-kang Li, Sheng-nan Dong, Wen-wen Liu, Qi Gong, Tian-duan-yi Wang, Yun Tang, Jin Zhu, Jian Li*, Hai-yan Zhang*, Fei Mao*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2018, 143, 33–47.

7. Xiaokang Li^#, Huan Wang^#, Yixiang Xu, Wenwen Liu, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. ACS Chem. Neurosci. 2017, 8, 2708–2721.

8. Yanli Lu^#, Fei Mao^#, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Qing Xu, Jin Zhu, and Jian Li*. Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs). J. Med. Chem. 2017, 60, 5099–5119.

9. Xiaokang Li^#, Huan Wang^#, Zhengyu Lu, Xinyu Zheng, Wei Ni, Jin Zhu, Yan Fu, Fulin Lian, Naixia Zhang, Jian Li*, Haiyan Zhang*, and Fei Mao*. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J. Med. Chem. 2016, 59, 8326−8344.

10. Fei Mao^#, Qingya Kong^#, Wei Ni, Xiang Xu, Dazheng Ling, Zhengyu Lu, Jian Li*. Melting point distribution analysis of the global approved and discontinued drugs: a Research for improving the success chance of drug design and discovery. ChemistryOpen, 2016, 5, 357–368.

11. Fei Mao, Wei Ni, Xiang Xu, Hui Wang, Jing Wang, Min Ji, Jian Li*. Chemical structure-related drug-like criteria of global approved drugs. Molecules 2016, 21, 75; doi:10.3390/molecules21010075.

12. Dengwei Wu^#, Fei Mao^#, Yan Ye, Jian Li, Chuanlian Xu*, Xiaomin Luo, Jing Chen*, Xu Shen. Policresulen as a novel inhibitor of NS2B/NS3 protease efficiently suppressed the replication of DENV2 virus. Acta Pharmacol. Sin. 2015, 36, 1126-1136.

13. Fei Mao, Jianheng Li, Hui Wei, Ling Huang*, Xingshu Li*. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease.J. Enzym. Inhib. Med. Chem.2015,30, 995-1001.

14. Fei Mao, Jun Yan, Jian-heng Li, Yang sun, Xian Jia, Ling Huang*, Xing-shu Li*. New Multi-Target-Directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol. Org. Biomol. Chem. 2014, 12, 5936-5944.

15. Fei Mao, Jian-wen Chen*, Qi Zhou, Zong-hua Luo, Li Huang, Xing-shu Li*. Novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. Bioorg. Med. Chem. Lett.2013, 23, 6737-6742.

16. Fei Mao, Ling Huang, Zong-hua Luo, Anqiu Liu, Chuan-jun Lu, Zhi-yong Xie*, Xingshu Li*. O-Hydroxyl or o-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation. Bioorgan. Med. Chem.2012, 20, 5884-5892.